Journal News

JLR: Cascading errors

How a mutation in a lipid-turnover pathway cause problems in others
Laurel Oldach
June 01, 2019
After endocytosis figureAfter endocytosis, membrane-spanning proteins or lipids that become part of an endosomal vesicle can face into the lumen of the late endosome and the lysosome. This makes parts of the molecule that were once on the cell surface accessible to enzymes in the lysosome.Adapted from Pribasnig et al./JBC 2015

Lysosomal storage disorders are genetic diseases. When any one of a number of enzymes in the lysosome loses its function, the molecule it breaks down accumulates, slowly building to levels that are toxic to cells. An article in the Journal of Lipid Research gives a clue as to why complex lipids known as gangliosides accumulate even in lysosomal storage disorders that don’t affect ganglioside metabolism directly. The work was led by Konrad Sandhoff, who discovered a lysosomal storage disorder (since named after him) in 1968.

The ganglioside GM2 is found mostly in the outer plasma membranes of cells in the nervous system. In Sandhoff disease, which is caused by mutation of the enzyme that cleaves the complex sugar in GM2’s head group, GM2 quickly accumulates in patients’ neuronal lysosomes. This accumulation can be neurologically debilitating and is often fatal.

After undergoing endocytosis as part of normal membrane turnover, GM2 becomes part of the surface of a vesicle in the lysosome (see figure). The enzyme that breaks down GM2, which resides in the lysosomal lumen, depends on binding between GM2 and an accessory protein called GM2AP to find and break down its substrate. Until now, researchers didn’t know whether GM2AP recruits the enzyme to the vesicle surface or delivers the lipid to the enzyme in solution.

Using surface plasmon resonance, scientists in Sandhoff’s lab led by postdoctoral fellow Susi Anheuser showed that GM2AP extracts gangliosides from the membrane of intraluminal vesicles. They also showed that GM2AP activity depends on the lipid makeup of those vesicles. If the vesicle has a negative surface charge, as is typical in healthy cells, GM2AP can extract gangliosides and ferry them to the relevant enzyme. If the quantity of neutral or positively charged lipids increases, the researchers observed, then that extraction is less effective, and ganglioside breakdown slows.

“GM2 degradation activity is regulated by molecules in the microenvironment of the reaction,” Sandhoff explained. “If the lipids are changed, you change everything.”

In addition to building up in some disorders as the main storage product, gangliosides can accumulate in disorders that primarily affect other lipids, such as cholesterol or mucopolysaccharides. Before now, scientists couldn’t explain why that secondary buildup occurred. This paper suggests that raising the concentration of these other lipids in the lysosomal vesicle disrupts ganglioside degradation by affecting the interaction between GM2AP and the vesicle surface.

Richard Proia was not involved with this JLR paper, but he studies sphingolipids at the National Institutes of Health. “Normally, simple-mindedly, you think of each enzyme carrying out a single reaction and working by itself,” he said, adding that this work complicates that view. “If one lipid is stored, and that has a negative effect on some other pathway, then the other pathways are now going to store lipids. That explains a phenomenon that’s been known for a long time.”

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Brain Injury Awareness Month 2021
Health Observance

Brain Injury Awareness Month 2021

March 01, 2021

In the U.S., about 2.8 million people sustain a traumatic brain injury annually. Learn about recent research on TBI-related dementia, dysfunctional mitochondria and other work powering the march toward better therapies.

The evolution of proteins from mysteries to medicines
Essay

The evolution of proteins from mysteries to medicines

February 27, 2021

An essay in observance of National Protein Day.

'Every experiment and every breakthrough matters'
Health Observance

'Every experiment and every breakthrough matters'

February 26, 2021

An interview with NYMC dean Marina K. Holz, who studies a rare disease that affects women of childbearing age.

Progeria: From the unknown to the first FDA-approved treatment
Health Observance

Progeria: From the unknown to the first FDA-approved treatment

February 25, 2021

Hutchinson–Gilford progeria syndrome is a rare, fatal genetic disease that causes premature aging.

Raising awareness and funding for Pompe disease
Health Observance

Raising awareness and funding for Pompe disease

February 25, 2021

Father-turned-advocate has founded multiple organizations to support families and search for better therapies for people with rare lysosomal storage disorder.

A novel approach to septic shock leads to a prospective new therapy
Journal News

A novel approach to septic shock leads to a prospective new therapy

February 23, 2021

A French research team finds new evidence supporting endotoxin removal for treating life-threatening inflammation.